|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Human epidermal growth factor receptor-2-positive breast cancer:Current management of early,advanced,and recurrent disease 显示文摘 | Callahan R Hurvitz S | 2011 | Curr Opin Obstet Gynecol2011，23，1： | 1 |
| 2 | RIBBON-2: a ran- domized, double-blind, placebo-controlled, phase m trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treat- ment of human epidermal growth factor receptor 2-neg- ative metastatic breast cancer 显示文摘 | Brufsky AM Hurvitz S Perez E | 2011 | J Clin Oncol2011，29，32： | 1 |
| 3 | Profiling and targeting HER2-posi-tive breast cancer using trastuzumab emtansine 显示文摘 | Sadeghi S Olevsky O Hurvitz SA | 2014 | PharmgenomicsPers Med2014，7，： | 1 |
| 4 | RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative me- tastatic breast cancer 显示文摘 | Brufsky A M Hurvitz S Perez E | 2011 | J Clin Oncol2011，29，32： | 1 |
| 5 | Phase M , randomized,double-blind, placebo-controlled study of ribociclib(LEE011) incombination with either tamoxifen and goserelin or a non-steroidalaromatase inhibitor (NSAI) and goserelin for the treatment ofpremenopausal women with HR+, HER2-advanced breast cancer(aBC):MONALEESA-7显示文摘 | Tripathy D Bardia A Hurvitz S A | 2015 | ASCO Meeting Abstracts2015，33，15： | 1 |
| 6 | Human epidermal growth factor receptor-2-positive breast cancer:current management of early,advanced,and recurrent disease显示文摘 | Callahan R Hurvitz S | | 0，，01： | 1 |
| 7 | RIBBON-2: a random- ized, double-blind, placebo-controlled, phase ~I trial evalua- ting the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer显示文摘 | Bmfsky AM Hurvitz S Perez E | 2011 | J Clin Oncol2011，29，32： | 1 |
| 8 | RIBBON-2:a random-ized,double-blind,placebo-controlled,phase III trial evalua-ting the efficacy and safety of bevacizumab in combination withchemotherapy for second-line treatment of human epidermalgrowth factor receptor 2-negative metastatic breast cancer显示文摘 | Brufsky AM Hurvitz S Perez E | 2011 | JClin Oncol2011，29，： | 1 |
| 9 | RIBBON-2: A randomized, double-Blind, placebo-controlled, phase Ⅲ trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer显示文摘 | Brufsky AM Hurvitz S Perez E | 2011 | J Clin Oncol2011，29，32： | 1 |
| 10 | Antibody-drug con- jugates:an emerging modality for the treatment of cancer 显示文摘 | LEAL M SAPRA P HURVITZ S A | 2014 | Ann New York Acad Sci2014，1321，： | 1 |
| 11 | RIBBON-2 : a ran-domized, double-blind, placebo-controlled, phase IH trialevaluating the efficacy and safety of bevacizumab in com-bination with chemotherapy for second-line treatment ofhuman epidermal growth factor receptor 2-negative meta-static breast cancer显示文摘 | Brufsky AM Hurvitz S Perez E | 2011 | J Clin Owco/2011，29，32： | 1 |
| 12 | Phase Ⅱ rand-omized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer 显示文摘 | HURVITZ S A DIRIX L KOCSIS J | 2013 | J Clin Oncol2013，31，23： | 1 |
| 13 | RIBBON-2: a random- ized, double-blind, placebo-controlled, phase III trial evaluat- ing the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer显示文摘 | Brufsky A M Hurvitz S Perez E | 2011 | J Clin Oncol2011，29，32： | 1 |
| 14 | RIBBON-2: A randomized, double-blind, placebo-controlled, phase Ⅲ trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer显示文摘 | Brufsky AM Hurvitz S Perez E | 2011 | J Clin Oncol2011，29，32： | 1 |
| 15 | Current approaches and future directions in the treatment of HER2-positive breast cancer显示文摘 | Hurvitz S A Hu Y O' Brien N | 2013 | Cancer Treat Rev2013，39，3： | 1 |
| 16 | Profiling and targeting HER2- positive breast cancer using trastuzumab Emtansine显示文摘 | Sadeghi S Olevsky O Hurvitz SA | 2014 | Pharma- cogenomics Pers Med2014，7，： | 1 |
| 17 | RIBBON-2: a random- ized, double-blind, placebo-controlled, phase Ⅲ trial evaluating the efficacy and safety of bevacizumab in combination with che- motherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer显示文摘 | Brufsky AM Hurvitz S Perez E | 2011 | J Clin Oncol2011，29，32： | 1 |
| 18 | Variable optical attenuator based on ion-exchange technology in glass 显示文摘 | HURVITZ T RUSCHIN S BROOKS D | 2005 | IEEE J Lightwave Tech2005，23，5： | 1 |
| 19 | RIBBON-2:A randomized,double-blind,placebo-controlled,phase iii trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cance显示文摘 | Brufsky AM Hurvitz S Perez E | | 0，，32： | 1 |
| 20 | RIBBON-2 Arandomized double-blind placebo-controlled phase Ⅲ trial evaluating the efficacy and safety of Bevacizumabin combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer显示文摘 | Brufsky AM Hurvitz S Perez E | | 0，，32： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员